SEARCH

SEARCH BY CITATION

References

  • Albers, G.W., Diener, H.C., Frison, L., Grind, M., Nevinson, M., Partridge, S., Halperin, J.L., Horrow, J., Olsson, S.B., Petersen, P. & Vahanian, A. (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA, 293, 690698.
  • Allison, P.D. (1995) Survival Analysis Using the SAS® System: A Practical Guide, pp. 1292. SAS Institute Inc., Cary, NC.
  • Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. & Palareti, G. (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 160S198S.
  • Azar, A.J., Cannegieter, S.C., Deckers, J.W., Briet, E., van Bergen, P.F., Jonker, J.J. & Rosendaal, F.R. (1996) Optimal intensity of oral anticoagulant therapy after myocardial infarction. Journal of the American College of Cardiology, 27, 13491355.
  • Beyth, R.J., Quinn, L.M. & Landefeld, C.S. (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. The American Journal of Medicine, 105, 9199.
  • Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., Darius, H., Diener, H.C., Joyner, C.D. & Wallentin, L. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361, 11391151.
  • DiMarco, J.P., Flaker, G., Waldo, A.L., Corley, S.D., Greene, H.L., Safford, R.E., Rosenfeld, L.E., Mitrani, G. & Nemeth, M. (2005) Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. American Heart Journal, 149, 650656.
  • van Es, R.F., Jonker, J.J., Verheugt, F.W., Deckers, J.W. & Grobbee, D.E. (2002) Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet, 360, 109113.
  • Fihn, S.D., Gadisseur, A.A., Pasterkamp, E., van der Meer, F.J., Breukink-Engbers, W.G., Geven-Boere, L.M., van Meegen, E., Vries-Goldschmeding, H., Antheunissen-Anneveld, I., van’t Hoff, A.R., Harderman, D., Smink, M. & Rosendaal, F.R. (2003) Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thrombosis and Haemostasis, 90, 260266.
  • Gage, B.F. & Lesko, L.J. (2008) Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. Journal of Thrombosis and Thrombolysis, 25, 4551.
  • Go, A.S., Hylek, E.M., Chang, Y., Phillips, K.A., Henault, L.E., Capra, A.M., Jensvold, N.G., Selby, J.V. & Singer, D.E. (2003) Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA, 290, 26852692.
  • Hermida, J., Zarza, J., Alberca, I., Montes, R., Lopez, M.L., Molina, E. & Rocha, E. (2002) Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood, 99, 42374239.
  • Hylek, E.M., Evans-Molina, C., Shea, C., Henault, L.E. & Regan, S. (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation, 115, 26892696.
  • Kucher, N., Connolly, S., Beckman, J.A., Cheng, L.H., Tsilimingras, K.V., Fanikos, J. & Goldhaber, S.Z. (2004) International normalized ratio increase before warfarin-associated hemorrhage - Brief and subtle. Archives of Internal Medicine, 164, 21762179.
  • Kuijer, P.M., Hutten, B.A., Prins, M.H. & Buller, H.R. (1999) Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Archives of Internal Medicine, 159, 457460.
  • Linkins, L.A., Choi, P.T. & Douketis, J.D. (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Annals of Internal Medicine, 139, 893900.
  • McCormick, D., Gurwitz, J.H., Goldberg, R.J., Becker, R., Tate, J.P., Elwell, A. & Radford, M.J. (2001) Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Archives of Internal Medicine, 161, 24582463.
  • van der Meer, F.J., Rosendaal, F.R., Vandenbroucke, J.P. & Briet, E. (1993) Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Archives of Internal Medicine, 153, 15571562.
  • van der Meer, F.J.M., Briet, E., Vandenbroucke, J.P., Sramek, D.I., Versluijs, M.H.P.M. & Rosendaal, F.R. (1997) The role of compliance as a cause of instability in oral anticoagulant therapy. British Journal of Haematology, 98, 893900.
  • Olsson, S.B. (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet, 362, 16911698.
  • Palareti, G. & Cosmi, B. (2009) Bleeding with anticoagulation therapy – who is at risk, and how best to identify such patients. Thrombosis and Haemostasis, 102, 268278.
  • Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D’Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., Devoto, G., Berrettini, M. & Musolesi, S. (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet, 348, 423428.
  • Palareti, G., Legnani, C., Guazzaloca, G., Lelia, V., Cosmi, B., Lunghi, B., Marchetti, G., Poli, D. & Pengo, V. (2005) Risks factors for highly unstable response to oral anticoagulation: a case-control study. British Journal of Haematology, 129, 7278.
  • Penning-van Beest, F.J.A., van Meegen, E., Rosendaal, F.R. & Stricker, B.H.C. (2001) Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thrombosis and Haemostasis, 86, 569574.
  • Reynolds, M.W., Fahrbach, K., Hauch, O., Wygant, G., Estok, R., Cella, C. & Nalysnyk, L. (2004) Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest, 126, 19381945.
  • Rosendaal, F.R., Cannegieter, S.C., van der Meer, F.J. & Briet, E. (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thrombosis and Haemostasis, 69, 236239.
  • Samsa, G.P., Matchar, D.B., Phillips, D.L. & McGrann, J. (2002) Which approach to anticoagulation management is best? Illustration of an interactive mathematical model to support informed decision making. Journal of Thrombosis and Thrombolysis, 14, 103111.
  • Schulman, S. & Kearon, C. (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis: JTH, 3, 692694.
  • Schulman, S., Beyth, R.J., Kearon, C. & Levine, M.N. (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: american college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest, 133, 257S298S.
  • Shireman, T.I., Mahnken, J.D., Howard, P.A., Kresowik, T.F., Hou, Q. & Ellerbeck, E.F. (2006) Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest, 130, 13901396.
  • The Stroke Prevention in Atrial Fibrillation Investigators (1996) Bleeding during antithrombotic therapy in patients with atrial fibrillation. Archives of Internal Medicine, 156, 409416.
  • Veeger, N.J., Piersma-Wichers, M., Tijssen, J.G., Hillege, H.L. & van der Meer, J. (2005) Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. a retrospective study of 2300 consecutive patients with venous thromboembolism. British Journal of Haematology, 128, 513519.
  • Veeger, N.J., Piersma-Wichers, M., Hillege, H.L., Crijns, H.J. & van der Meer, J. (2006) Early detection of patients with a poor response to vitamin K antagonists: the clinical impact of individual time within target range in patients with heart disease. Journal of Thrombosis and Haemostasis: JTH, 4, 16251627.
  • White, R.H., McKittrick, T., Takakuwa, J., Callahan, C., McDonell, M. & Fihn, S. (1996) Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. Archives of Internal Medicine, 156, 11971201.
  • Wilkinson, G.R. (2005) Drug therapy – drug metabolism and variability among patients in drug response. New England Journal of Medicine, 352, 22112221.
  • Wittkowsky, A.K. (2005) Factors associated with INR elevation and bleeding complications during warfarin therapy. Archives of Internal Medicine, 165, 703.
  • Wittkowsky, A.K. & Devine, E.B. (2004) Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy, 24, 13111316.